J&J Defends Duragesic, Ortho Evra Patches
This article was originally published in The Pink Sheet Daily
Executive Summary
Safety of transdermal delivery system is not undermined by recent reports of adverse events with the products, the firm says. Mylan defends its own transdermal fetanyl patch, stating that FDA safety review pertains to Duragesic.